From 20 October till 24 October 2023: HIGHLIGHTS FROM ESMO
Your direct line with Madrid
The European Society of Medical Oncology (ESMO) 2023 brings together leading experts in the different fields of cancer from around the world. And this year they gather together in Madrid, Spain. The MediMix team is also onsite, and will – together with your Belgian colleagues – keep you posted about the hottest topics as they happen. And, we dive into posters and hot topics with the experts as they are being presented.
Stay tuned, and get ready for an exciting and informative journey!
Latest daily highlights
Two clinical trials were conducted to assess the role of radiotherapy in the treatment of locally advanced rectal cancer. In the CONVERT trial, neoadjuvant chemotherapy (nCT) with CAPOX alone was
Two investigations were presented concerning RAS-wildtype unresectable metastatic colon cancer, employing FOLFOXIRI treatment paired with the antibody therapy cetuximab.
The first, TRICE, was a randomized clinical trial comparing the chemotherapy
The advanTIG trial aimed to assess the impact of adding ociperlimab (OCI) to the standard care regimen of tislelizumab (TIS) + BAT1706 (a bevacizumab biosimilar) in advanced hepatocellular carcinoma. The
In the field of non-metastatic non-small cell lung cancer (NSCLC), Professor Lore Decoster, a medical oncologist at UZ Brussels, made a selection of abstracts presented during the proffered session on
With the educational support of: